Avalo Therapeutics Inc (AVTX)
NASDAQHealth CareBiotechnologySnapshot 2026-09-04
$19.23+1.21%
Close 2026-09-04 · 1-day change
NASDAQHealth CareBiotechnologySnapshot 2026-09-04
QuarterlyIQ Insights · AVTX
How strong the business is — where it ranks within its sector on capital efficiency and cash generation, and how well management has been executing.
How management runs the business: capital, margins, balance sheet, and how reliably they guide and deliver.
A guidance track record builds as the company issues and delivers on guidance.
Priorities management has stated in recent disclosures, with status and evidence drawn from earnings calls, filings, and press releases.
Initiate a registrational Phase 3 clinical trial for abdakibart in hidradenitis suppurativa in first half of 2027 following positive Phase 2 results.
Stated as a priority in 2 of last 2 quarters. Management announced plans to initiate a registrational Phase 3 program for abdakibart in hidradenitis suppurativa in the first half of 2027, following positive Phase 2 LOTUS trial results reported in 2026-Q1. The company is delivering on this priority by progressing clinical development as planned.
Each factor is a parallel diagnostic with a clear read of what it shows and how names like it have historically fared. Never aggregated into a single score.
Operating income rose in 0 of the last 3 quarter-over-quarter moves. Historically, Health Care names rated weak grew net income 28% of the time over the next year (vs 52% for the rest of the cohort, n=10029).
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
“Plans to initiate a registrational Phase 3 program evaluating abdakibart in HS in the first half of 2027.”
“Plan to advance abdakibart into a registrational phase 3 program following positive Phase 2 LOTUS results.”
Advance development of AVTX-010, a long-acting next-generation anti-IL-1β monoclonal antibody, with IND submission planned for first half of 2027.
Newly stated in 2026-Q2. Management announced the advancement of AVTX-010 with an IND submission planned for the first half of 2027. This represents a strategic pipeline expansion beyond abdakibart. No prior quarters mention this priority, so delivery is at an early stage.
“Announced advancement of AVTX-010, a long-acting next-generation anti-IL-1β antibody, with IND submission planned for first half of 2027.”
Manage financial resources prudently to ensure cash runway extends into 2029, supporting ongoing operations and development programs.
Stated as a priority in 2 of last 2 quarters. Management reported cash, cash equivalents and investments increased from $82.0 million at 2026-Q1 to $472.2 million at 2026-Q2, supporting a cash runway expected into 2029. This reflects strong capital discipline and successful financing execution, delivering on the stated priority.
“Cash, cash equivalents and investments of $472.2 million as of June 30, 2026, expected to provide runway into 2029.”
“Cash, cash equivalents and short-term investments were $82.0 million as of March 31, 2026, expected to fund operations into 2029.”
Continue development of clinical programs including Phase 2 and Phase 3 trials and explore additional indications for IL-1β inhibitors.
Stated as a priority in 2 of last 2 quarters. Management emphasized advancing abdakibart into Phase 3 and expanding the IL-1β pipeline. While no specific financial or clinical milestones beyond Phase 2 results are reported yet, the company is maintaining focus on clinical development execution, indicating ongoing progress.
“Focus now is execution starting with advancing abdakibart toward Phase 3 initiation and building a broader IL-1β franchise.”
“Exploring additional opportunities to make an impact in prevalent indications with significant unmet needs.”
Pursue mergers, acquisitions, and partnerships to strengthen pipeline and commercial capabilities.
Newly stated in 2026-Q1. Management disclosed a milestone buyout option agreement related to the AlmataBio acquisition, involving payments of $2.25 million and an option for $5.125 million in cash or stock instead of a $15 million milestone. This indicates active management of M&A-related obligations but limited further updates since.
“Entered into Milestone Buyout Option Agreement and Amendment related to AlmataBio acquisition.”
Over the trailing year it converted 0.23x of net income into operating cash flow.
Not enough signal yet.
Not enough signal to read sensitivity to the broad stock market, the US dollar, real (inflation-adjusted) rates, long-term interest rates, Fed net liquidity (low R² over the window).
14 material management or governance events in the past 24 months, led by executive changes. Historically, Health Care names rated neutral grew net income 53% of the time over the next year (vs 49% for the rest of the cohort, n=5275).
Not investment advice. As of 2026-09-04.